This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Khan, R. Search for Related Content Social Bookmarking                         What's this?

Weight gain and insulin therapy

Basildon Hospital, Nethermayne, Basildon, Essex, SS16 5NL, UK, dr_rehman_khan{at}hotmail.com

Weight gain is common with insulin therapy in type 1 and type 2 diabetes. Excessive weight gain worsens glycaemic control and increases cardiovascular risk. It can also increase diabetic morbidity and mortality if it acts as a psychological barrier to initiation or intensification of insulin therapy, or affects compliance. Insulin-associated weight gain might result from conservation of previously excreted glucose, defensive `snacking' caused by fear or experience of hypoglycaemia, or the `unphysiological' pharmacokinetic profiles that follow sc insulin administration. Strategies to limit insulin-mediated weight gain include increasing insulin sensitivity through dietary modification, exercise or insulin sensitising drugs. Attempts to replace insulin using regimens that accurately mimic physiological norms should also enable insulin to be dosed with maximum efficiency. The novel analogue insulin, detemir, has not of the pharmacological mechanisms underlying this shown the usual propensity for weight gain. Elucidation of the pharmacological mechanisms property could further clarify mechanism linking insulin with weight regulation.

Key Words: diabetes mellitus • insulin • weight gain • mechanisms • limiting weight gain • insulin detemir.

References

• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998;280:140-6.[Abstract/Free Full Text]
• The DCCT Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:171121.
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(suppl 3):S18-S24.
• Snoek FJ Breaking the barriers to optimal glycaemic control--what physicians need to know from patients' perspectives. Int J Clin Pract Suppl 2002;(129):80-4.[Medline] [Order article via Infotrieve]
• Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF Insulin omission in women with IDDM. Diabetes Care 1994;17:117885.
• Bryden KS, Neil A., Mayou RA, Peveler RC, Fairburn CG, Dunger DB Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes. Diabetes Care 1999; 22:1956-60.[Abstract/Free Full Text]
• Anderson JW, Kendall CW, Jenkins DJ Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9.[Abstract/Free Full Text]
• Carlson MG, Campbell PJ Intensive insulin therapy and weight gain in IDDM. Diabetes 1993;42:1700-07.[Abstract]
• The DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care 1988; 11:567-73.[Abstract]
• Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-82.[CrossRef][Medline] [Order article via Infotrieve]
• Chen JW, Christiansen JS, Lauritzen T. Limitations to subcutaneous insulin administration in type 1 diabetes. Diabetes Obes Metab 2003;5: 223-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Heise T., Nosek L., Biilmann Rønn B. et al. Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People with Type 1 Diabetes. Diabetes 2004;53:1614-20.[Abstract/Free Full Text]
• Saudek CD Novel forms of insulin delivery. Endocrinol Metab Clin North Am 1997;26:599-610.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Laville M., Andreelli F. Mechanisms for weight gain during blood glucose normalization. Diabetes Metab 2000;26(suppl 30):42-5.[Web of Science][Medline] [Order article via Infotrieve]
• Reaven GM Beneficial effect of moderate weight loss in older patients with non-insulin-dependent diabetes mellitus poorly controlled with insulin. J Am Geriatr Soc 1985;33(2):93-5.[Web of Science][Medline] [Order article via Infotrieve]
• Spiegelman BM Peroxisome proliferator-activated receptor gamma: A key regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res 1997;28:457-64.
• Scarpello JH Improving survival with metformin: the evidence base today. Diabetes Metab 2003;29(4 Pt 2):6S36-43.[Medline] [Order article via Infotrieve]
• Mamputu JC, Wiernsperger NF, Renier G. Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab 2003;29(4 Pt 2):6S71-6.[Medline] [Order article via Infotrieve]
• Johnson M. Krosnick A., Carson P., McDade AM, Laraway K. A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes. Clin Ther 1998;20:691-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hamilton J., Cummings E., Zdravkovic V., Finegood D., Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003;26: 138-43.[Abstract/Free Full Text]
• Day C., Archer H.,Bailey CJ Recent advances in insulin therapy. Br J Cardiol 2003;10:379-83.
• De Leeuw I., Selam J-L., Skeie S., Elte JWF, Lang H., Vague P. Insulin detemirbased used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain press. over 12 months in comparison to NPH insulin. Diab Obes Metab 2004;in
• Standl E., Roberts A., Lang H., Draeger E. Long-term efficacy and safety of insulin detemir in subjects with type 1 diabetes. Favorable weight development and risk reduction of nocturnal hypoglycemia. Diabetes 2002;51(suppl 2):A115.
• Vague P., Selam JL, Skeie S. et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-6.[Abstract/Free Full Text]
• Home P., Bartley P., Russell-Jones D. et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial. Diabetes Care 2004;27:1081-7.[Abstract/Free Full Text]
• Russell-Jones D., Draeger E., Simpson R., Bolinder J., Hylleberg B. Effects of once-daily insulin detemir or NPH insulin on blood glucose control in people with type 1 diabetes using a basal-bolus regimen. Clin Ther 2004;26:724-36.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hermansen K., Fontaine P., Kukolja KK, Peterkova V., Leth G., Gall MA Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004 [Epub ahead of print].
• Haak T., Tiengo A., Draeger E., Suntum M., Waldhäusl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diab Obes Metab 2004;in press.
• Pieber TR, Plank J., Goerzer E. et al. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes. Diabetes 2002;51(suppl 2):A53.[CrossRef]

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 4, 264-267 (2004)
DOI: 10.1177/14746514040040040901


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Khan, R. Search for Related Content Social Bookmarking                         What's this?